Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease.
Brandes J, Zobel I, Rohmann N, Schlicht K, Geisler C, Hartmann K, Türk K, von Schönfels W, Beckmann J, Tran F, Laudes M. Brandes J, et al. Among authors: tran f. Sci Rep. 2022 Sep 2;12(1):14935. doi: 10.1038/s41598-022-18354-x. Sci Rep. 2022. PMID: 36056109 Free PMC article.
Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections.
Schlicht K, Rohmann N, Geisler C, Hollstein T, Knappe C, Hartmann K, Schwarz J, Tran F, Schunk D, Junker R, Bahmer T, Rosenstiel P, Schulte D, Türk K, Franke A, Schreiber S, Laudes M. Schlicht K, et al. Among authors: tran f. Int J Obes (Lond). 2020 Nov;44(11):2335-2338. doi: 10.1038/s41366-020-00689-y. Epub 2020 Sep 21. Int J Obes (Lond). 2020. PMID: 32958905 Free PMC article.
Correction: Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections.
Schlicht K, Rohmann N, Geisler C, Hollstein T, Knappe C, Hartmann K, Schwarz J, Tran F, Schunk D, Junker R, Bahmer T, Rosenstiel P, Schulte D, Türk K, Franke A, Schreiber S, Laudes M. Schlicht K, et al. Among authors: tran f. Int J Obes (Lond). 2022 Jan;46(1):243. doi: 10.1038/s41366-021-00988-y. Int J Obes (Lond). 2022. PMID: 34671109 Free PMC article. No abstract available.
A novel unconventional T cell population enriched in Crohn's disease.
Rosati E, Rios Martini G, Pogorelyy MV, Minervina AA, Degenhardt F, Wendorff M, Sari S, Mayr G, Fazio A, Dowds CM, Hauser C, Tran F, von Schönfels W, Pochhammer J, Salnikova MA, Jaeckel C, Gigla JB, Sabet SS, Hübenthal M, Schiminsky E, Schreiber S, Rosenstiel PC, Scheffold A, Thomas PG, Lieb W, Bokemeyer B, Witte M, Aden K, Hendricks A, Schafmayer C, Egberts JH, Mamedov IZ, Bacher P, Franke A. Rosati E, et al. Among authors: tran f. Gut. 2022 Nov;71(11):2194-2204. doi: 10.1136/gutjnl-2021-325373. Epub 2022 Mar 9. Gut. 2022. PMID: 35264446 Free PMC article.
Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection.
Rohmann N, Stürmer P, Geisler C, Schlicht K, Hartmann K, Türk K, Hollstein T, Tran F, Rosenstiel P, Franke A, Heyckendorf J, Schreiber S, Schulte DM, Laudes M. Rohmann N, et al. Among authors: tran f. Front Immunol. 2022 Oct 13;13:1037115. doi: 10.3389/fimmu.2022.1037115. eCollection 2022. Front Immunol. 2022. PMID: 36311771 Free PMC article.
Effects of lifestyle and associated diseases on serum CC16 suggest complex interactions among metabolism, heart and lungs.
Rohmann N, Stürmer P, Geisler C, Schlicht K, Knappe C, Hartmann K, Türk K, Hollstein T, Beckmann A, Seoudy AK, Becker U, Wietzke-Braun P, Settgast U, Tran F, Rosenstiel P, Beckmann JH, von Schönfels W, Seifert S, Heyckendorf J, Franke A, Schreiber S, Schulte DM, Laudes M. Rohmann N, et al. Among authors: tran f. J Adv Res. 2024 May;59:161-171. doi: 10.1016/j.jare.2023.06.005. Epub 2023 Jun 16. J Adv Res. 2024. PMID: 37330047 Free PMC article.
Dynamic changes in extracellular vesicle-associated miRNAs elicited by ultrasound in inflammatory bowel disease patients.
Tran F, Scharmacher A, Baran N, Mishra N, Wozny M, Chavez SP, Bhardwaj A, Hinz S, Juzenas S, Bernardes JP, Sievers LK, Lessing M, Aden K, Lassen A, Bergfeld A, Weber HJ, Neas L, Vetrano S, Schreiber S, Rosenstiel P. Tran F, et al. Sci Rep. 2024 May 13;14(1):10925. doi: 10.1038/s41598-024-61532-2. Sci Rep. 2024. PMID: 38740826 Free PMC article.
Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, Conrad C, Avalos D, Jaeckel C, Scherer M, Sørensen SB, Overgaard SH, Schulte B, Nikolaus S, Rey G, Gasparoni G, Lyons PA, Schultze JL, Walter J, Andersen V; SYSCID Consortium; Dermitzakis ET, Schreiber S, Rosenstiel P. Mishra N, et al. Among authors: tran f. Genome Med. 2022 Sep 24;14(1):110. doi: 10.1186/s13073-022-01112-z. Genome Med. 2022. PMID: 36153599 Free PMC article.
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, Volk V, Mishra N, Blase JI, Nikolaus S, Bethge J, Kühbacher T, Röcken C, Chen M, Cottingham I, Petri N, Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F, Rose-John S, Waetzig GH, Rosenstiel P. Schreiber S, et al. Among authors: tran f. Gastroenterology. 2021 Jun;160(7):2354-2366.e11. doi: 10.1053/j.gastro.2021.02.062. Epub 2021 Mar 2. Gastroenterology. 2021. PMID: 33667488 Free article. Clinical Trial.
160 results